Are you on the hunt for big returns to supercharge your portfolio?
If you are, then it could pay to listen to what analysts are saying about the ASX 200 growth stocks listed below.
Here's why analysts are feeling bullish about these stocks and are tipping them to rise strongly from current levels:
Image source: Getty Images
Neuren Pharmaceuticals Ltd (ASX: NEU)
Bell Potter thinks that Neuren Pharmaceuticals could be a great option for growth investors.
It is a pharmaceuticals company that is developing new drug therapies to treat multiple serious neurological disorders that emerge in early childhood and have no or limited approved treatment options.
Bell Potter is feeling bullish due to the ASX 200 growth stock's product pipeline. It notes that the NNZ-2591 product candidate in particular has the potential to be a big revenue generator. It is being trialled in children with Angelman syndrome. It explains:
Neuren Pharmaceuticals is a biotech company that is well-funded via its first asset, DAYBUE, which is an FDA approved trofinetide for the treatment of Rett syndrome. NEU's value is from its second asset, NNZ-2591, which is under development for rare diseases. NNZ-2591, if successful, could lead to a significant increase in revenue and earnings when brought to market. NEU looks attractive on a risk/adjusted basis after the recent sell-off.
Bell Potter has a buy rating and $25.00 price target on its shares. Based on its current share price of $12.27, this implies potential upside of 103% for investors.
Treasury Wine Estates Ltd (ASX: TWE)
Another ASX 200 growth stock that could be destined to rise strongly from current levels is Treasury Wine.
It is the wine giant behind a portfolio of popular brands. This includes Penfolds, Wolf Blass, Lindeman's, and 19 Crimes.
Morgans is positive on the company and appears to believe the market is undervaluing its shares. Particularly if the recent acquisition of DAOU Vineyards delivers on expectations. It said:
It may take some time for the market to digest TWE's acquisition of Paso Robles luxury wine business, DAOU Vineyards (DAOU) for US$900m (A$1.4bn) given it required a large capital raising. The acquisition is in line with TWE's premiumisation and growth strategy and will strengthen a key gap in Treasury Americas (TA) portfolio.
Importantly, DAOU has generated solid earnings growth and is a high margin business. It consequently allowed TWE to upgrade its margins targets. While not without risk given the size of this transaction, if TWE delivers on its investment case, there is material upside to our valuation.
Morgans currently has an add rating and $15.03 price target on its shares. Based on its current share price of $11.28, this suggests that upside of 33% is possible over the next 12 months.
